Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Goldline Pharmaceuti IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2004 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 8.46 Cr
Profile
Price Range 41  to  43 per share
Profile
Min Investment ₹43
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the “Goldline” brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.The products are marketed and sold exclusively under the “Goldline” brand. Our customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, we maintain contractual arrangements with 15 manufacturers and 7 distributors, ensuring a stable supply chain and consistent market presence.Our Company also extend comprehensive material supply and procurement support to hospitals and healthcare partners. Through our promoter group entities as Numerius Healthcare Pvt Ltd (Formerly Known As Enrich Healthcare & PSPL International) & Activista Healthcare Pvt Ltd (Formerly Known As Gold N Gold Distributors). Our Company manage trading and supply chain operations, thereby ensuring reliable procurement, seamless distribution, and logistical efficiency.Our Promoters, Mr. Amol Laxmikant Mujumdar and Mr. Swapan Premprakash Khandelwal, with 25 years and 30 years of experience respectively in pharmaceutical marketing and supply chain management, have been instrumental in shaping the growth and strategic direction of the Company. Their expertise continues to drive our business expansion and operational resilience. Read More

Basic Info

Face Value 10 per share

Price 41  to  43 per share

P/E (x) 10.5

Sales( Cr.) 28

PAT( Cr.) 3

EPS 4.1

Draft Prospectus

Exchange BSE-SME

Promoter

Company Promoters

Amol Laxmikant Mujumdar Swapan Premprakash Khandelwal

Pre Issue Share Holding 79.7%

Post Issue Share Holding 57.29%

Listing Details:

Listing Price: 59.75

Listing Gain: 28.03%

Current Price: 48.4

Gain On Issue: 48.4 | 0%

GMP: 15

GMP %: 34.9 %

IPO Tentative Timetable

Opening Date May 12, 2026
Closing Date May 14, 2026
Allotment May 15, 2026
Refund May 18, 2026
Delivery of Shares May 18, 2026
Listing Date May 19, 2026

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 6000 258,000
Retail (Max) -- -- --
S-HNI (Min) 1 6000 258,000
S-HNI (Max) 3 18000 774,000
B-HNI (Min) 4 24000 1,032,000

Objective of the Issue

1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our Company 2. General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 540000 97317000 180.2x
NII 528000 648333000 1227.9x
Retail 900000 793038000 881.2x
EMP 0 0 0x
Total 1968000 1538688000 781.9x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Goldline Pharmaceuti Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 20 24 28
Other Income 0 0 0
Total Income 20 24 28
Total Expenditure 18 19 22
Operating Profit 2 4 6
Interest 2 2 2
Depreciation 0 0 0
Exceptional Income / Expenses 0 0 0
Profit Before Tax 0 3 4
Provision for Tax 0 1 1
Profit After Tax 0 2 3
Adjustments 0 0 0
Profit After Adjustments 0 2 3
Adjusted Earnings Per Share 0.4 2.6 4.1

Goldline Pharmaceuti Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 6 8 10
Minority's Interest 0 0 0
Borrowings 4 4 3
Other Non-Current Liabilities 1 1 1
Total Current Liabilities 9 10 12
Total Liabilities 19 23 26
Fixed Assets 2 3 3
Other Non-Current Assets 0 0 0
Total Current Assets 17 20 23
Total Assets 19 23 26

Goldline Pharmaceuti Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 1
Cash Flow from Operating Activities 2 3 2
Cash Flow from Investing Activities -1 -1 0
Cash Flow from Financing Activities -1 -1 -2
Net Cash Inflow / Outflow -0 1 0
Closing Cash & Cash Equivalent 0 1 1

Goldline Pharmaceuti Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.43 2.62 4.11
CEPS(Rs) 0.72 2.86 4.47
DPS(Rs) 0 0 0
Book NAV/Share(Rs) 6.81 8.78 12.39
Core EBITDA Margin(%) 11.13 18.26 21.59
EBIT Margin(%) 10.25 17.57 20.69
Pre Tax Margin(%) 2.02 10.72 13.75
PAT Margin (%) 1.29 7.66 10.1
Cash Profit Margin (%) 2.18 8.36 10.99
ROA(%) 1.32 8.53 11.52
ROE(%) 6.28 35.62 38.81
ROCE(%) 12.17 23.18 28.75
Receivable days 158.65 141.33 132.15
Inventory Days 98.76 99.6 92.81
Payable days 57.32 79.87 64.28
PER(x) 0 0 0
Price/Book(x) 0 0 0
Dividend Yield(%) 0 0 0
EV/Net Sales(x) 0.73 0.61 0.66
EV/Core EBITDA(x) 6.6 3.36 3.06
Net Sales Growth(%) 0 18.73 19.05
EBIT Growth(%) 0 103.44 40.24
PAT Growth(%) 0 603.82 56.93
EPS Growth(%) 0 511.97 56.93
Debt/Equity(x) 1.84 1.42 1.07
Current Ratio(x) 1.87 1.92 1.98
Quick Ratio(x) 1.27 1.18 1.41
Interest Cover(x) 1.25 2.57 2.98
Total Debt/Mcap(x) 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 17% 0% 0% 0%
Operating Profit CAGR 50% 0% 0% 0%
PAT CAGR 50% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 39% 27% 27% 27%
ROCE Average 29% 21% 21% 21%

Company Contact Information

Goldline Pharmaceutical Ltd.

Ruchi Sanket Modi

91 712 278 6666

info@goldlinepharma.in

103, F-1, Leela Apartment Shilpa Hsg Society Near Saptagiri Nagar, Shanidham, Narendra Nagar

IPO Lead Manager(s)

Goldline Pharmaceutical Ltd.

Cumulative Capital Pvt Ltd

Registrar Info

Goldline Pharmaceutical Ltd.

Bigshare Services Pvt Ltd

G 10 Left Wing Amruta Village , Opp: Yashoda Hospital,Raj Bhavan Road,Somajiguda,Hyderabad

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!